Arixtra adds treatment indications
Executive Summary
Sanofi-Synthelabo's antithrombotic Arixtra (fondaparinux) clears FDA May 28 for treatment of deep vein thrombosis and pulmonary embolism. The product, previously approved for prophylactic use in patients undergoing hip fracture surgery and hip or knee replacement, is being divested to GlaxoSmithKline in conjunction with Sanofi's pending acquisition of Aventis (1"The Pink Sheet" April 19, 2004, p. 18)...
You may also be interested in...
GSK Will Buy Arixtra From Sanofi If Aventis Merger Goes Through
GlaxoSmithKline's conditional acquisition of Sanofi's antithrombotic brands would give GSK an almost free chance to build a potentially significant new product line in the U.S
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.